Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP

Journal of Alzheimer's Disease

Volumn 28, Issue 4, 2012, Pages 961-969

  Boddapati, Shanta ^a   Levites, Yona ^b   Suryadi, Vick ^a   Kasturirangan, Srinath ^a   Sierks, Michael R ^a  

^a Arizona State University   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

A PP processing; bispecific tandem scFv; secretase; secretase

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; INHIBITION KINETICS; MODULATION; NEUROPROTECTION; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84858052507     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111196     Document Type: Article

References (43)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122. (Pubitemid 36975801)
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
3. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
4. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
5. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
6. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537.
7. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540.
8. Kopan R, Ilagan MX (2004) Gamma-secretase: Proteasome of the membrane? Nat Rev Mol Cell Biol 5, 499-504.
9. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124.
10. Sisodia SS (1992) Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci U S A 89, 6075-6079.
11. Wolfe MS (2002) Secretase as a target for Alzheimer's disease. Curr Top Med Chem 2, 371-383.
12. Hunt CE, Turner AJ (2009) Cell biology, regulation and inhibition of beta-secretase (BACE-1). FEBS J 276, 1845-1859.
13. Arbel M, Yacoby I, Solomon B (2005) Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci U S A 102, 7718-7723. (Pubitemid 40741037)
14. Boddapati S, Levites Y, Sierks MR (2011) Inhibiting beta-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. J Mol Biol 405, 436-447.
15. Wolfe MS (2008) Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 5, 391-398.
16. Samson K (2010) NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues. Ann Neurol 68, A9-A12.
17. Fahrenholz F (2007) Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4, 412-417.
18. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552.
19. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273, 32730-32738. (Pubitemid 28557658)
20. Skidgel RA, Erdos EG (2004) Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: A brief history, the beginning and follow-ups to early studies. Peptides 25, 521-525. (Pubitemid 38591559)
21. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR (2003) Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 42, 14328-14334. (Pubitemid 37499430)
22. Kasturirangan S, Brune D, Sierks M (2009) Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. Biotechnol Prog 25, 1054-1063.
23. Kasturirangan S, Boddapati S, Sierks MR (2010) Engineered proteolytic nanobodies reduce Aβ burden and ameliorate Aβ-induced cytotoxicity. Biochemistry 49, 4501-4508.
24. Kontermann RE (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26, 1-9.
25. Korn T, Nettelbeck DM, Volkel T, Muller R, Kontermann RE (2004) Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: A comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6, 642-651. (Pubitemid 40228080)
26. Selkoe DJ (2004) Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6, 1054-1061.
27. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
28. Weiner HL, Frenkel D (2006) Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6, 404-416.
29. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9-12.
30. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-A31.
31. Hooper NM, Turner AJ (2002) The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer's disease. Curr Med Chem 9, 1107-1119. (Pubitemid 34568187)
32. Cole SL, Vassar R (2007) The Basic Biology of BACE1: A key therapeutic target for Alzheimer's disease. Curr Genomics 8, 509-530. (Pubitemid 351472400)
33. Check E (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462.
34. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54. (Pubitemid 36818745)
35. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252.
36. Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ (2007) Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171, 241-251. (Pubitemid 47339241)
37. Eckman EA, Eckman CB (2005) Aβ-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33, 1101-1105. (Pubitemid 41659123)
38. Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, Roher AE, de Prat Gay G, Morelli L, Castano EM (2008) The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: Implications for Alzheimer disease pathogenesis. J Biol Chem 283, 17039-17048.
39. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Aβ peptide: The many roads to perdition. Neuron 43, 605-608. (Pubitemid 39179722)
40. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499. (Pubitemid 32038587)
41. Lazarov O, Marr RA (2010) Neurogenesis and Alzheimer's disease: At the crossroads. Exp Neurol 223, 267-281.
42. Fersht A (1985) Enzyme structure and mechanism, W.H. Freeman, New York, pp. 56-63.
43. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 4036-4042. (Pubitemid 44078091)